E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Nearsightedness |
Kurzsichtigkeit |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the amplitude of accommodation |
Beurteilung der Akkommodationsbreite |
|
E.2.2 | Secondary objectives of the trial |
The investigation of treatment effects as reflected by clinical endpoints of visual functions, accommodation velocity, pupil reaction, choroidal thickness are secondary aims of the trial. |
Die Untersuchung von Behandlungsauswirkungen anhand der klinischen Endpunkte Sehfunktionen, Akkommodationsgeschwindigkeit, Pupillenverhalten, Aderhautdicke sind sekundäre Ziele der Studie. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Children and adolescents for whom the decision was already made for treatment with 0.01% atropine based on their individual situation (eye length, observed myopia progression) and after thorough information discussion about the special status of the myopia. Determining indications for treatment and general consultation will be based on the recommendations of the scientific medical societies. • Age 6-17 years • Myopia progression of at least 0.5 dpt in the last 12 months in at least on eye • Myopia below 4.0 dpt • Written consent of at least one legal guardian and assent of the subject |
• Kinder und Jugendliche, bei denen die Entscheidung zu einer Behandlung mit 0,01% Atropin auf Grund der individuellen Situation (Augenlänge, beobachtete Progression der Myopie) nach einem ausführlichen Aufklärungsgespräch über den Sonderstatus der Myopie bereits getroffen wurde. Die Indikationsstellung und allgemeine Beratung orientiert sich an den Empfehlungen der wissenschaftlichen Fachgesellschaften. • Alter 6-17 Jahre • Myopieprogression mindestens 0,5 dpt in den vergangenen 12 Monaten auf mindestens einem Auge • Myopie unter 4,0 dpt • Schriftliches Einverständnis mindestens eines Erziehungsberechtigten und des/r Probanden/in |
|
E.4 | Principal exclusion criteria |
• Anisometropia > 1.0 dpt. • Astigmatism > 1.5 Dpt. • Best corrected vision < 0.8 • Eye diseases other than myopia, in particular changes of the conjunctiva, scarring of the cornea and diseases of the anterior segment of the eye • Known intolerance of atropine eye drops • Participation in another clinical trial within the last 30 days |
• Anisometropie > 1,0 dpt. • Astigmatismus > 1,5 Dpt. • Bestkorrigierter Visus < 0,8 • Erkrankungen des Auges außer der Myopie, insbesondere Veränderungen der Bindehaut, Narben der Hornhaut und Erkrankungen des vorderen Augenabschnitts • Bekannte Unverträglichkeit auf Atropin-Augentropfen • Teilnahme an einer anderen klinischen Studie innerhalb der letzten 30 Tage |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Amplitude of accommodation |
Akkommodationsbreite |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After end of study |
Nach Studienende |
|
E.5.2 | Secondary end point(s) |
Accommodation velocity Local tolerability Systemic tolerability Pupil diameter and reaction Contrast sensitivity Light/dark adaptation Glare sensitivity OCT angiography and EDI-OCT Anterior segment OCT Volume of the ciliary muscle |
Akkommodationsgeschwindigkeit Lokale Verträglichkeit Systemische Verträglichkeit Pupillendurchmesser und –reaktion Kontrastempfindlichkeit Hell-Dunkel-Adaption Blendungsempfindlichkeit OCT-Angiographie und EDI-OCT Vorderabschnitts-OCT Volumen des M.ciliaris |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After end of study |
Nach Studienende |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |